Debt Securities, Available-for-sale [Abstract] Schedule of Available-for-sale Securities Reconciliation Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of Marketable Securities Marketable Securities [Table Text Block] Investments Classified by Contractual Maturity Date Investments Classified by Contractual Maturity Date [Table Text Block] Fair Value Disclosures [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Marketable securities - available for sale Investments, Fair Value Disclosure Assets, fair value disclosure Assets, Fair Value Disclosure Accrued Liabilities [Abstract] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options Share-based Payment Arrangement, Option [Member] Warrants Warrant [Member] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Loss Per Share Earnings Per Share [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cash and cash equivalents Cash Marketable securities Marketable Securities Total Cash, Cash Equivalents, and Short-term Investments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation Issuance of Stock and Warrants for Services or Claims Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Accretion on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Accounts payable, accrued liabilities and other liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of marketable securities Payments to Acquire Marketable Securities Sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Tax withholding payments on net share settlement equity awards Payment, Tax Withholding, Share-based Payment Arrangement Net proceeds from issuance of common stock Proceeds from Issuance or Sale of Equity Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Leases [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other assets Other Assets [Member] Accrued liabilities Accrued Liabilities [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Balance Sheet Captions Assets and Liabilities, Lessee [Abstract] Right-of-use assets Operating Lease, Right-of-Use Asset Operating lease liabilities, current Operating Lease, Liability, Current Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Operating lease liabilities Operating Lease, Liability Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Project [Axis] Project [Axis] Project [Domain] Project [Domain] CD34 cell technology Ischemic Repair CD34 Cell Technology [Member] Ischemic Repair CD34 Cell Technology [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Grants awarded Grants Receivable Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Available-for-Sale-Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Salaries, employee benefits and related taxes Employee-related Liabilities, Current Operating lease liabilities -- current CIRM upfront funding -- current Accrued Grant Funding Accrued Grant Funding Other Other Accrued Liabilities, Current Total accrued liabilities Accrued Liabilities, Current Commitments and Contingencies Disclosure [Abstract] Contingencies Commitments and Contingencies Disclosure [Text Block] Statement of Financial Position [Abstract] Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, liquidation value Preferred Stock, Liquidation Preference, Share Preferred Stock, Liquidation Preference, Share Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares designated Preferred stock, shares designated Preferred stock, shares designated Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares, outstanding Common Stock, Shares, Outstanding Treasury stock (shares) Treasury Stock, Shares Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Total Caladrius Biosciences, Inc. Stockholders' Equity Parent [Member] Series B Convertible Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Treasury Stock Treasury Stock [Member] Non- Controlling Interest in Subsidiary Noncontrolling Interest [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] [Domain] for Cumulative Effect, Period of Adoption [Axis] Adoption of accounting standard Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative Effect, Period of Adoption, Adjustment [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance (shares) Shares, Outstanding Beginning Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Unrealized gain on marketable securities Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Share-based compensation (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Share-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Net proceeds from issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Net proceeds from issuance of common stock Stock Issued During Period, Value, New Issues Ending Balance (shares) Ending Balance Finance Minimum Lease Payments Finance Lease, Liability, Payment, Due [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Income Statement [Abstract] Operating Expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Other income: Nonoperating Income (Expense) [Abstract] Investment income, net Other Nonoperating Income (Expense) Total other income Nonoperating Income (Expense) Net loss Less - net income attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders Net Income (Loss) Attributable to Parent Basic and diluted loss per share Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Caladrius Biosciences, Inc. common stockholders (in usd per share) Earnings Per Share, Basic and Diluted Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and diluted shares Weighted Average Number of Shares Outstanding, Basic and Diluted Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Share-based Payment Arrangement, Noncash Expense [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Axis] Total share-based compensation expense Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative Selling, General and Administrative Expenses [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation expense Share-based Payment Arrangement, Expense Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Expected weighted-average period in years of compensation cost to be recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total fair value of shares vested APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Weighted average estimated fair value of shares granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Schedule Share-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Total Compensation Cost Related to Nonvested Awards Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Fair Value of Share-based Compensation Awards Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block] Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block] Schedule of Future Minimum Lease Payments Under Lease Agreements Lessee, Operating Lease, Liability, Maturity [Table Text Block] ASSETS Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Prepaid and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Total current liabilities Liabilities, Current Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments and Contingencies Stockholders' Equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2020 and December 31, 2019, respectively Preferred Stock, Value, Issued Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 10,638,771 and 10,528,689 shares at March 31, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock, at cost; 11,080 shares at March 31, 2020 and December 31, 2019 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Total Caladrius Biosciences, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total stockholders' equity Liabilities and Equity, Total Liabilities and Equity Share-Based Compensation Share-based Payment Arrangement [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Sale of Stock [Domain] RD Purchase Agreement RD Purchase Agreement [Member] RD Purchase Agreement [Member] Private placement Private Placement [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Proceeds from sale of NOLs Proceeds From Sale Of Net Operating Losses, NJEDA Program Proceeds From Sale Of Net Operating Losses, NJEDA Program Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Price of shares sold (in dollars per share) Sale of Stock, Price Per Share Number of shares called by warrants issued Class of Warrant or Right, Number of Securities Called by Warrants or Rights Gross price for stock transaction Sale of Stock, Consideration Received on Transaction Number of shares called by each warrant Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants expiration term Warrants and Rights Outstanding, Term Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Corporate debt securities Corporate Debt Securities [Member] Money market funds Money Market Funds [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Debt Securities, Available-for-sale Research and Development [Abstract] Research Funding Research, Development, and Computer Software Disclosure [Text Block] Operating Leases Lessee, Operating Leases [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Number of offices under operating leases Number Of Offices Under Operating Leases Number Of Offices Under Operating Leases Weighted average remaining lease term for operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate for operating leases (percent) Operating Lease, Weighted Average Discount Rate, Percent Statement of Comprehensive Income [Abstract] Available for sale securities - net unrealized (loss) income Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Total other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Lincoln Park Agreement Lincoln Park Agreement [Member] Lincoln Park Agreement [Member] H.C. Wainwright Sales Amended Agreement H.C. Wainwright Sales Amended Agreement [Member] H.C. Wainwright Sales Amended Agreement [Member] Class of Stock [Line Items] Class of Stock [Line Items] Aggregate offering amount authorized per agreement Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement Commitment shares issued as consideration per agreement (in shares) Stock Issued During Period, Shares, Issued As Consideration Stock Issued During Period, Shares, Issued As Consideration Term of agreement (in months) Term Of Agreement Term Of Agreement Number of shares allowable to direct for Regular Purchase (in shares) Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase Maximum obligation per directed purchase transaction for Regular Purchase Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent) Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent) Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period Maximum beneficial ownership allowable per agreement (percent) Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty Commission on gross proceeds due to third party (percent) Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent Aggregate market of common stock held by non-affiliates Aggregate Market Value Of Common Stock, Non-Affiliates Aggregate Market Value Of Common Stock, Non-Affiliates Maximum number of shares authorized per agreement (in shares) Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement Stock issued (shares) Proceeds from issuance of stock Proceeds from Issuance of Common Stock Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract] Less than one year Debt Securities, Available-for-sale, Maturity, Remainder of Fiscal Year, Amortized Cost Greater than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost Estimated Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Less than one year Debt Securities, Available-for-sale, Maturity, Remainder of Fiscal Year, Fair Value Greater than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value Total estimated fair value Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Stockholders' Equity Note, Stock Options and warrants [Table] Class of Warrant or Right [Table] Stock Options Activity [Axis] Stock Options Activity [Axis] Stock Options Activity [Axis] Stock Options Activity [Domain] Stock Options Activity [Domain] Stock Options Activity [Domain] US Equity Plan [Member] US Equity Plan [Member] US Equity Plan [Member] Stock Options and Warrants [Line Items] Class of Warrant or Right [Line Items] Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options, Outstanding, Beginning of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options, Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options, Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options, Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options, Outstanding, End of Period (in shares) Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options, Outstanding. Beginning of Period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options, Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options, Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Options, Outstanding, End of Period (in dollars per share) Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options, Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options, Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options, Vested and expected to vest, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options, Vested and expected to vest, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options, Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options, Vested, Weighted Average Exercise Price (in dollars per share) Options, Vested, Weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Options, Vested, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Warrants Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Warrants, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Warrants, Outstanding, Beginning of Period (in shares) Common Stock Warrants, Shares Common Stock Warrants, Shares Warrants, Granted (in shares) Warrants Granted Warrants Granted Warrants, Exercised (in shares) Warrants Exercised Warrants Exercised Warrants, Forfeited (in shares) Warrants Canceled Warrants Canceled Warrants, Expired (in shares) Warrants Expired Warrants Expired Warrants, Outstanding, End of Period (in shares) Warrants Weighted Average Exercise Price [Roll Forward] Warrants Weighted Average Exercise Price [Roll Forward] Warrants Weighted Average Exercise Price [Roll Forward] Warrants, Granted (in dollars per share) Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Granted Warrants, Exercised (in dollars per share) Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Exercised Warrants, Forfeited (in dollars per share) Weighted Average Exercise Price, Warrants Canceled Weighted Average Exercise Price, Warrants Canceled Warrants, Expired (in dollars per share) Weighted Average Exercise Price, Warrants Expired Weighted Average Exercise Price, Warrants Expired Warrants Outstanding, End of Period (in dollars per share) Weighted Average Exercise Price, Warrants Outstanding Weighted Average Exercise Price, Warrants Outstanding Warrants, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term warrant outstanding Weighted Average Remaining Contractual Term warrant outstanding Warrants Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants Outstanding Aggregate Intrinsic Value, Warrants Outstanding Warrants, Vested and expected to vest (in shares) shares, vested and expected to vest shares, vested and expected to vest Weighted Average Exercise Price, Warrants Vested And Expected To Vest Weighted Average Exercise Price, Warrants Vested And Expected To Vest Weighted Average Exercise Price, Warrants Vested And Expected To Vest Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Warrants, Vested and expected to vest, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested and expected to vest Aggregate Intrinsic Value, Warrants vested and expected to vest Warrants, Vested (in shares) Warrants, Vested Warrants, Vested Warrants, Vested, Weighted Average Exercise Price (in dollars per share) Weighted Average Exercise Price, Warrants Exercisable Weighted Average Exercise Price, Warrants Exercisable Warrants, Vested, Weighted Average Remaining Contractual Term weighted Average Remaining Contractual Term, warrants vested weighted Average Remaining Contractual Term, warrants vested Warrants, Vested, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested Aggregate Intrinsic Value, Warrants vested The Business The Business [Text Block] The Business [Text Block] Schedule of Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Number of restricted stock issued Stock Issued During Period, Shares, Restricted Stock Award, Gross Value of restricted stock issued Stock Issued During Period, Value, Restricted Stock Award, Gross Weighted average estimated fair value of restricted stock issued Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vesting terms (years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Concentration of Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal Domestic Tax Authority [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating loss carryforwards Operating Loss Carryforwards Market capitalization used in net operating loss analysis Market Capitalization Used In Net Operating Loss Analysis Market Capitalization Used In Net Operating Loss Analysis Annual limitation on usage of net operating losses Net Operating Loss Analysis, Annual Limitation Net Operating Loss Analysis, Annual Limitation Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Funding of grant award Funding Of Grant Award, Cash Received Funding Of Grant Award, Cash Received Milestone payment received on grant award Milestone Payment On Grant Award, Cash Received Milestone Payment On Grant Award, Cash Received Progress payment received on grant award Progress Payment On Grant Award, Cash Received Progress Payment On Grant Award, Cash Received Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Accrued grant funding Amortization of accrued grant funding to offset expense Amortization Of Accrued Grant Funding Liability To Offset Expense Amortization Of Accrued Grant Funding Liability To Offset Expense